Tagged with china

China Dr Tianyi (Tee) Zhang, GM of Frontage China and SVP of Frontage Holdings, shares the significant growth of the China affiliate over the past four years; their competitive advantages in China with both bio-analytical and clinical services, their close collaborations with key hospitals, and their ‘Two Countries, One System’ philosophy…

China Dr Jiang Lei and Dr Shou Jianyong, EnnovaBio’s co-founders, introduce their strategy and outline the progress being made in the Chinese biopharma industry at large.   We are a Chinese company so we really want to benefit Chinese patients and meet unmet medical needs in China. Otherwise, why would we…

China Dr Shun Luo, chairman, founder and CEO of Thousand Oaks Biopharmaceuticals, shares the company’s vision to deliver more accessible and affordable biologics to patients globally by lowering the cost of goods manufactured (COGM) per gram of recombinant protein; the paradigm-shifting technology and processes Thousand Oaks Biopharmaceuticals is innovating as an…

China Catherine Lee, general manager and managing director of West Pharmaceutical Services China, shares the highlights of her 2.5 years heading West’s China affiliate; West’s commitment to delivering their global scientific leadership and technical solutions to the Chinese market; how West simplifies the journey with their new Integrated Solutions program to…

China Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high school chemistry teacher, and Zhong, a former factory technician, overtake Robin Li, founder of Chinese search engine giant Baidu, and…

China Dr Jinzi Jason Wu of Ascletis – a Chinese biotech success story that has developed rapidly in recent years – outlines the company’s journey from its founding in 2013 to now having two products on the market in China, having IPOed in Hong Kong and with a presence across the…

China PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in China, but local players are already releasing their own drugs, sometimes at a third of the price. This represents a…

China More accessible and affordable healthcare for all: China’s government has outlined several proposals to expand healthcare reform in a report released 4th June by the General Office of the State Council. These proposals include improving disease and treatment systems, expanding rural healthcare, and reforming hospital management and pricing.    Health…

China The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both countries and regulatory reform underway in China, Indian firms are jumping at the chance to bring their competitively-priced drugs to…

China The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the second largest biotech funding hub in the world.    Hansoh Pharmaceutical, one of China’s fastest-growing pharma companies, raised a billion…

Hong Kong With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the successes that the Hong Kong exchange has already seen and the exciting and diverse future listings in the pipeline.  …

China China is a hot topic in Big Pharma investor updates these days. The world’s second-largest pharmaceutical market boasts sales growth that continuously surpasses that of the US and other developed regions. However, with the rollout of the “4+7” procurement scheme slashing drug prices, industry insiders are predicting a more turbulent…